A new meta-analysis of six randomized trials reports that CagriSema significantly lowers HbA1c, body weight, and blood pressure in type 2 diabetes, with efficacy and tolerability differences varying by dose. The integrated view supports CagriSema’s multi-parameter impact rather than a single biomarker outcome. The analysis evaluates across trial-level datasets and positions dose selection as a key determinant of clinical benefit. For developers and payers, the message strengthens the case for dosing strategy as part of the label-relevant value proposition. The findings also emphasize the practical need to interpret effectiveness across endpoints—glycemic control, weight, and cardiometabolic risk proxies—when considering real-world prescribing. Industry stakeholders will likely use the dose-response framing to inform comparator positioning versus other incretin-based regimens and to guide patient selection. The meta-analysis doesn’t replace head-to-head trials, but it adds sharper dose guidance for ongoing clinical and market planning.